WEKO3
アイテム
{"_buckets": {"deposit": "b871e0ba-e207-4856-a006-2d68857ab7d9"}, "_deposit": {"created_by": 6, "id": "26957", "owners": [6], "pid": {"revision_id": 0, "type": "depid", "value": "26957"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00026957", "sets": ["2015"]}, "author_link": ["120029", "120030", "120031", "120033", "120032"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2021-10-25", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageStart": "1989789", "bibliographicVolumeNumber": "10", "bibliographic_titles": [{"bibliographic_title": "OncoImmunology"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Human Vγ2Vδ2 (also termed Vγ9Vδ2) T cells play important roles in microbial and tumor immunity by monitoring foreign- and self-prenyl pyrophosphate metabolites in isoprenoid biosynthesis. Accumulation of isoprenoid metabolites after bisphosphonate treatment allows Vγ2Vδ2 T cells to recognize and kill tumors independently of their MHC expression or burden of non-synonymous mutations. Clinical trials with more than 400 patients show that adoptive immunotherapy with Vγ2Vδ2 T cells has few side effects but has resulted in only a few partial and complete remissions. Here, we have tested Vγ2Vδ2 T cells for expression of inhibitory receptors and determined whether adding PD-1 checkpoint blockade to adoptively transferred Vγ2Vδ2 T cells enhances immunity to human PC-3 prostate tumors in an NSG mouse model. We find that Vγ2Vδ2 T cells express PD-1, CTLA-4, LAG-3, and TIM-3 inhibitory receptors during the 14-day ex vivo expansion period, and PD-1, LAG-3, and TIM-3 upon subsequent stimulation by pamidronate-treated tumor cells. Expression of PD-L1 on PC-3 prostate cancer cells was increased by co-culture with activated Vγ2Vδ2 T cells. Importantly, anti-PD-1 mAb treatment enhanced Vγ2Vδ2 T cell immunity to PC-3 tumors in immunodeficient NSG mice, reducing tumor volume nearly to zero after 5 weeks. These results demonstrate that PD-1 checkpoint blockade can enhance the effectiveness of adoptive immunotherapy with human γδ T cells in treating prostate tumors in a preclinical model.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "OncoImmunology, 10(1), art. no. 1989789; 2021", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Taylor \u0026 Francis Group, LLC."}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1080/2162402X.2021.1989789", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© 2021 The Author(s). Published with license by Taylor \u0026 Francis Group, LLC. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited."}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "2162-402X", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Nada, Mohanad H."}], "nameIdentifiers": [{"nameIdentifier": "120029", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Wang, Hong"}], "nameIdentifiers": [{"nameIdentifier": "120030", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hussein, Auter J."}], "nameIdentifiers": [{"nameIdentifier": "120031", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tanaka, Yoshimasa"}], "nameIdentifiers": [{"nameIdentifier": "120032", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Morita, Craig T."}], "nameIdentifiers": [{"nameIdentifier": "120033", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2021-12-23"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "OncoImmunology10_1989789.pdf", "filesize": [{"value": "2.0 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 2000000.0, "url": {"label": "OncoImmunology10_1989789.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/26957/files/OncoImmunology10_1989789.pdf"}, "version_id": "a70e451c-3aa4-4d2b-aed3-4aced58d5192"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Adoptive immunotherapy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "programed cell death 1", "subitem_subject_scheme": "Other"}, {"subitem_subject": "receptor", "subitem_subject_scheme": "Other"}, {"subitem_subject": "prostatic", "subitem_subject_scheme": "Other"}, {"subitem_subject": "neoplasms", "subitem_subject_scheme": "Other"}, {"subitem_subject": "inhibitory T cell", "subitem_subject_scheme": "Other"}, {"subitem_subject": "receptors", "subitem_subject_scheme": "Other"}, {"subitem_subject": "combined", "subitem_subject_scheme": "Other"}, {"subitem_subject": "modality therapy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "human γδ T cells", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Vγ2Vδ2 T cells", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "PD-1 checkpoint blockade enhances adoptive immunotherapy by human Vγ2Vδ2 T cells against human prostate cancer", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "PD-1 checkpoint blockade enhances adoptive immunotherapy by human Vγ2Vδ2 T cells against human prostate cancer"}]}, "item_type_id": "2", "owner": "6", "path": ["2015"], "permalink_uri": "http://hdl.handle.net/10069/00041122", "pubdate": {"attribute_name": "公開日", "attribute_value": "2021-12-23"}, "publish_date": "2021-12-23", "publish_status": "0", "recid": "26957", "relation": {}, "relation_version_is_last": true, "title": ["PD-1 checkpoint blockade enhances adoptive immunotherapy by human Vγ2Vδ2 T cells against human prostate cancer"], "weko_shared_id": -1}
PD-1 checkpoint blockade enhances adoptive immunotherapy by human Vγ2Vδ2 T cells against human prostate cancer
http://hdl.handle.net/10069/00041122
http://hdl.handle.net/10069/0004112275079a0b-ce55-452a-8fa6-4031b85707a3
名前 / ファイル | ライセンス | アクション |
---|---|---|
OncoImmunology10_1989789.pdf (2.0 MB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2021-12-23 | |||||
タイトル | ||||||
タイトル | PD-1 checkpoint blockade enhances adoptive immunotherapy by human Vγ2Vδ2 T cells against human prostate cancer | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Adoptive immunotherapy | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | programed cell death 1 | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | receptor | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | prostatic | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | neoplasms | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | inhibitory T cell | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | receptors | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | combined | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | modality therapy | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | human γδ T cells | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Vγ2Vδ2 T cells | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Nada, Mohanad H.
× Nada, Mohanad H.× Wang, Hong× Hussein, Auter J.× Tanaka, Yoshimasa× Morita, Craig T. |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Human Vγ2Vδ2 (also termed Vγ9Vδ2) T cells play important roles in microbial and tumor immunity by monitoring foreign- and self-prenyl pyrophosphate metabolites in isoprenoid biosynthesis. Accumulation of isoprenoid metabolites after bisphosphonate treatment allows Vγ2Vδ2 T cells to recognize and kill tumors independently of their MHC expression or burden of non-synonymous mutations. Clinical trials with more than 400 patients show that adoptive immunotherapy with Vγ2Vδ2 T cells has few side effects but has resulted in only a few partial and complete remissions. Here, we have tested Vγ2Vδ2 T cells for expression of inhibitory receptors and determined whether adding PD-1 checkpoint blockade to adoptively transferred Vγ2Vδ2 T cells enhances immunity to human PC-3 prostate tumors in an NSG mouse model. We find that Vγ2Vδ2 T cells express PD-1, CTLA-4, LAG-3, and TIM-3 inhibitory receptors during the 14-day ex vivo expansion period, and PD-1, LAG-3, and TIM-3 upon subsequent stimulation by pamidronate-treated tumor cells. Expression of PD-L1 on PC-3 prostate cancer cells was increased by co-culture with activated Vγ2Vδ2 T cells. Importantly, anti-PD-1 mAb treatment enhanced Vγ2Vδ2 T cell immunity to PC-3 tumors in immunodeficient NSG mice, reducing tumor volume nearly to zero after 5 weeks. These results demonstrate that PD-1 checkpoint blockade can enhance the effectiveness of adoptive immunotherapy with human γδ T cells in treating prostate tumors in a preclinical model. | |||||
書誌情報 |
OncoImmunology 巻 10, 号 1, p. 1989789, 発行日 2021-10-25 |
|||||
出版者 | ||||||
出版者 | Taylor & Francis Group, LLC. | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 2162-402X | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1080/2162402X.2021.1989789 | |||||
権利 | ||||||
権利情報 | © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | OncoImmunology, 10(1), art. no. 1989789; 2021 |